Announcement • May 25
Vivo Bio Tech Limited to Report Q4, 2026 Results on May 29, 2026 Vivo Bio Tech Limited announced that they will report Q4, 2026 results on May 29, 2026 Valuation Update With 7 Day Price Move • Mar 30
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹21.05, the stock trades at a trailing P/E ratio of 10.3x. Average trailing P/E is 28x in the Life Sciences industry in India. Total returns to shareholders of 5.8% over the past three years. Reported Earnings • Feb 15
Third quarter 2026 earnings released: EPS: ₹0.56 (vs ₹0.55 in 3Q 2025) Third quarter 2026 results: EPS: ₹0.56 (up from ₹0.55 in 3Q 2025). Revenue: ₹136.5m (up 12% from 3Q 2025). Net income: ₹12.5m (up 52% from 3Q 2025). Profit margin: 9.1% (up from 6.7% in 3Q 2025). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Announcement • Feb 02
Vivo Bio Tech Limited to Report Q3, 2026 Results on Feb 13, 2026 Vivo Bio Tech Limited announced that they will report Q3, 2026 results on Feb 13, 2026 Valuation Update With 7 Day Price Move • Dec 24
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹32.06, the stock trades at a trailing P/E ratio of 17.3x. Average trailing P/E is 33x in the Life Sciences industry in India. Total returns to shareholders of 6.9% over the past three years. New Risk • Dec 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.9x net interest cover). High level of non-cash earnings (29% accrual ratio). Shareholders have been substantially diluted in the past year (48% increase in shares outstanding). Market cap is less than US$10m (₹733.5m market cap, or US$8.18m). Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Profit margins are more than 30% lower than last year (8.2% net profit margin). New Risk • Nov 16
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 8.9% Last year net profit margin: 16% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). High level of non-cash earnings (29% accrual ratio). Shareholders have been substantially diluted in the past year (48% increase in shares outstanding). Market cap is less than US$10m (₹737.1m market cap, or US$8.31m). Minor Risk Profit margins are more than 30% lower than last year (8.9% net profit margin). Reported Earnings • Nov 16
Second quarter 2026 earnings released: EPS: ₹0.45 (vs ₹3.51 in 2Q 2025) Second quarter 2026 results: EPS: ₹0.45 (down from ₹3.51 in 2Q 2025). Revenue: ₹132.4m (up 10.0% from 2Q 2025). Net income: ₹8.69m (down 83% from 2Q 2025). Profit margin: 6.6% (down from 44% in 2Q 2025). Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Announcement • Nov 04
Vivo Bio Tech Limited to Report Q2, 2026 Results on Nov 14, 2025 Vivo Bio Tech Limited announced that they will report Q2, 2026 results on Nov 14, 2025 Announcement • Aug 26
Vivo Bio Tech Limited, Annual General Meeting, Sep 30, 2025 Vivo Bio Tech Limited, Annual General Meeting, Sep 30, 2025. Reported Earnings • Aug 13
First quarter 2026 earnings released: EPS: ₹0.74 (vs ₹0.11 in 1Q 2025) First quarter 2026 results: EPS: ₹0.74 (up from ₹0.11 in 1Q 2025). Revenue: ₹126.5m (up 25% from 1Q 2025). Net income: ₹13.4m (up ₹11.7m from 1Q 2025). Profit margin: 11% (up from 1.6% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Announcement • Aug 07
Vivo Bio Tech Limited to Report Q1, 2026 Results on Aug 12, 2025 Vivo Bio Tech Limited announced that they will report Q1, 2026 results on Aug 12, 2025 New Risk • Jul 04
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 33% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.5x net interest cover). Shareholders have been substantially diluted in the past year (33% increase in shares outstanding). Market cap is less than US$10m (₹734.7m market cap, or US$8.60m). Reported Earnings • May 21
Full year 2025 earnings released: EPS: ₹4.76 (vs ₹1.70 in FY 2024) Full year 2025 results: EPS: ₹4.76 (up from ₹1.70 in FY 2024). Revenue: ₹514.8m (up 13% from FY 2024). Net income: ₹72.8m (up 188% from FY 2024). Profit margin: 14% (up from 5.6% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Board Change • May 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Non-Executive Independent Director Shyam Tipparaju was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • May 14
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹40.88, the stock trades at a trailing P/E ratio of 10.3x. Average trailing P/E is 47x in the Life Sciences industry in India. Total returns to shareholders of 3.2% over the past three years. Valuation Update With 7 Day Price Move • Apr 17
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹40.64, the stock trades at a trailing P/E ratio of 10.2x. Average trailing P/E is 48x in the Life Sciences industry in India. Total loss to shareholders of 9.1% over the past three years. New Risk • Apr 10
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 17% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.6x net interest cover). Market cap is less than US$10m (₹609.7m market cap, or US$7.07m). Minor Risk Shareholders have been diluted in the past year (17% increase in shares outstanding). Valuation Update With 7 Day Price Move • Feb 17
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₹37.96, the stock trades at a trailing P/E ratio of 8.8x. Average trailing P/E is 50x in the Life Sciences industry in India. Total loss to shareholders of 1.4% over the past three years. Reported Earnings • Jan 10
Third quarter 2025 earnings released: EPS: ₹0.55 (vs ₹0.89 in 3Q 2024) Third quarter 2025 results: EPS: ₹0.55 (down from ₹0.89 in 3Q 2024). Revenue: ₹122.1m (down 5.0% from 3Q 2024). Net income: ₹8.20m (down 38% from 3Q 2024). Profit margin: 6.7% (down from 10% in 3Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. New Risk • Jan 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.6x net interest cover). Earnings have declined by 2.2% per year over the past 5 years. Market cap is less than US$10m (₹737.9m market cap, or US$8.61m). Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change). Valuation Update With 7 Day Price Move • Jan 06
Investor sentiment improves as stock rises 33% After last week's 33% share price gain to ₹49.51, the stock trades at a trailing P/E ratio of 9.9x. Average trailing P/E is 55x in the Life Sciences industry in India. Total loss to shareholders of 33% over the past three years. Announcement • Jan 02
Vivo Bio Tech Limited to Report Q3, 2025 Results on Jan 09, 2025 Vivo Bio Tech Limited announced that they will report Q3, 2025 results at 12:15 PM, Indian Standard Time on Jan 09, 2025 Reported Earnings • Nov 16
Second quarter 2025 earnings released: EPS: ₹3.51 (vs ₹0.22 in 2Q 2024) Second quarter 2025 results: EPS: ₹3.51 (up from ₹0.22 in 2Q 2024). Revenue: ₹166.7m (up 80% from 2Q 2024). Net income: ₹52.3m (up ₹49.1m from 2Q 2024). Profit margin: 31% (up from 3.5% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Announcement • Oct 31
Vivo Bio Tech Limited to Report Q2, 2025 Results on Nov 14, 2024 Vivo Bio Tech Limited announced that they will report Q2, 2025 results on Nov 14, 2024 Announcement • Aug 27
Vivo Bio Tech Limited, Annual General Meeting, Sep 30, 2024 Vivo Bio Tech Limited, Annual General Meeting, Sep 30, 2024, at 15:00 Indian Standard Time. Reported Earnings • Aug 11
First quarter 2025 earnings released: EPS: ₹0.11 (vs ₹0.10 in 1Q 2024) First quarter 2025 results: EPS: ₹0.11 (up from ₹0.10 in 1Q 2024). Revenue: ₹101.5m (down 12% from 1Q 2024). Net income: ₹1.66m (up 17% from 1Q 2024). Profit margin: 1.6% (up from 1.2% in 1Q 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 21% per year whereas the company’s share price has fallen by 22% per year. Announcement • Aug 02
Vivo Bio Tech Limited to Report Q1, 2025 Results on Aug 10, 2024 Vivo Bio Tech Limited announced that they will report Q1, 2025 results at 3:30 PM, Indian Standard Time on Aug 10, 2024 Reported Earnings • May 21
Full year 2024 earnings released: EPS: ₹1.70 (vs ₹1.79 in FY 2023) Full year 2024 results: EPS: ₹1.70 (down from ₹1.79 in FY 2023). Revenue: ₹454.9m (down 13% from FY 2023). Net income: ₹25.3m (down 4.6% from FY 2023). Profit margin: 5.6% (up from 5.1% in FY 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings. Announcement • May 08
Vivo Bio Tech Limited to Report Q4, 2024 Results on May 20, 2024 Vivo Bio Tech Limited announced that they will report Q4, 2024 results on May 20, 2024 Valuation Update With 7 Day Price Move • Mar 12
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₹40.11, the stock trades at a trailing P/E ratio of 15.5x. Average trailing P/E is 30x in the Life Sciences industry in India. Total loss to shareholders of 27% over the past three years. Reported Earnings • Feb 14
Third quarter 2024 earnings released: EPS: ₹0.89 (vs ₹0.10 in 3Q 2023) Third quarter 2024 results: EPS: ₹0.89 (up from ₹0.10 in 3Q 2023). Revenue: ₹128.8m (down 4.9% from 3Q 2023). Net income: ₹13.2m (up ₹11.7m from 3Q 2023). Profit margin: 10% (up from 1.1% in 3Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Announcement • Jan 31
Vivo Bio Tech Limited to Report Q3, 2024 Results on Feb 12, 2024 Vivo Bio Tech Limited announced that they will report Q3, 2024 results on Feb 12, 2024 Announcement • Jan 23
Vivo Bio Tech Limited Appoints Vaishnavi Kiran Ayinampudi as Company Secretary & Compliance Officer Vivo Bio Tech Limited at its board meeting held on January 23, 2024 appointed Mr. Vaishnavi Kiran Ayinampudi (Membership No: A60906), as the Company Secretary & Compliance Officer of the Company with effect from 23rd January, 2024. Mr. Vaishnavi Kiran Ayinampudi is an Associate member of the Institute of Company Secretaries of India (ICSI). He has over two and half years of experience in dealing with Secretarial Compliances of Listed and Unlisted Companies. Valuation Update With 7 Day Price Move • Jan 02
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹40.88, the stock trades at a trailing P/E ratio of 22.7x. Average trailing P/E is 22x in the Life Sciences industry in India. Total loss to shareholders of 37% over the past three years. Reported Earnings • Nov 16
Second quarter 2024 earnings released: EPS: ₹0.22 (vs ₹0.08 in 2Q 2023) Second quarter 2024 results: EPS: ₹0.22 (up from ₹0.08 in 2Q 2023). Revenue: ₹92.6m (down 27% from 2Q 2023). Net income: ₹3.27m (up 172% from 2Q 2023). Profit margin: 3.5% (up from 1.0% in 2Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. Announcement • Nov 04
Vivo Bio Tech Limited to Report Q2, 2024 Results on Nov 14, 2023 Vivo Bio Tech Limited announced that they will report Q2, 2024 results on Nov 14, 2023 Valuation Update With 7 Day Price Move • Oct 26
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₹30.89, the stock trades at a trailing P/E ratio of 18.6x. Average trailing P/E is 23x in the Life Sciences industry in India. Total loss to shareholders of 25% over the past three years. Valuation Update With 7 Day Price Move • Sep 11
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹33.00, the stock trades at a trailing P/E ratio of 19.9x. Average trailing P/E is 27x in the Life Sciences industry in India. Total loss to shareholders of 21% over the past three years. Board Change • Sep 06
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Non Independent Non Executive Director Shivanand Karopadi was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Sep 02
Vivo Bio Tech Limited, Annual General Meeting, Sep 30, 2023 Vivo Bio Tech Limited, Annual General Meeting, Sep 30, 2023, at 15:00 Indian Standard Time. Announcement • Sep 01
Vivo Bio Tech Limited Announces the Resignation of Hariharan Ravindran as Independent Director Vivo Bio Tech Limited announced that at the board meeting held on August 31, 2023, the company approved the resignation of Mr. Hariharan Ravindran as Independent Director of the Company, with effect from August 31, 2023. Reported Earnings • Aug 08
First quarter 2024 earnings released: EPS: ₹0.10 (vs ₹0.22 in 1Q 2023) First quarter 2024 results: EPS: ₹0.10 (down from ₹0.22 in 1Q 2023). Revenue: ₹115.8m (up 2.8% from 1Q 2023). Net income: ₹1.42m (down 55% from 1Q 2023). Profit margin: 1.2% (down from 2.8% in 1Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Announcement • Jul 25
Vivo Bio Tech Limited to Report Q1, 2024 Results on Aug 07, 2023 Vivo Bio Tech Limited announced that they will report Q1, 2024 results on Aug 07, 2023 Valuation Update With 7 Day Price Move • Jun 06
Investor sentiment improves as stock rises 33% After last week's 33% share price gain to ₹30.66, the stock trades at a trailing P/E ratio of 17.2x. Average trailing P/E is 29x in the Life Sciences industry in India. Total returns to shareholders of 6.8% over the past three years. Reported Earnings • Jun 04
Full year 2023 earnings released: EPS: ₹1.78 (vs ₹1.56 in FY 2022) Full year 2023 results: EPS: ₹1.78 (up from ₹1.56 in FY 2022). Revenue: ₹522.7m (up 1.7% from FY 2022). Net income: ₹26.5m (up 20% from FY 2022). Profit margin: 5.1% (up from 4.3% in FY 2022). Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Announcement • May 19
Vivo Bio Tech Limited to Report Q4, 2023 Results on May 30, 2023 Vivo Bio Tech Limited announced that they will report Q4, 2023 results on May 30, 2023 Reported Earnings • Feb 15
Third quarter 2023 earnings released: EPS: ₹0.10 (vs ₹0.97 in 3Q 2022) Third quarter 2023 results: EPS: ₹0.10 (down from ₹0.97 in 3Q 2022). Revenue: ₹135.4m (up 4.8% from 3Q 2022). Net income: ₹1.49m (down 89% from 3Q 2022). Profit margin: 1.1% (down from 11% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Announcement • Jan 31
Vivo Bio Tech Limited to Report Q3, 2023 Results on Feb 13, 2023 Vivo Bio Tech Limited announced that they will report Q3, 2023 results at 3:30 PM, Indian Standard Time on Feb 13, 2023 Announcement • Dec 22
Vivo Bio Tech Limited announced a financing transaction Vivo Bio Tech Limited announced a private placement of equity shares/warrants by way of a preferential allotment on December 21, 2022. The transaction has been approved by the board of directors of the company at their meeting and is subject to regulatory/ statutory approvals. Reported Earnings • Nov 20
Second quarter 2023 earnings released: EPS: ₹0.08 (vs ₹0.20 in 2Q 2022) Second quarter 2023 results: EPS: ₹0.08 (down from ₹0.20 in 2Q 2022). Revenue: ₹126.8m (up 25% from 2Q 2022). Net income: ₹1.21m (down 56% from 2Q 2022). Profit margin: 1.0% (down from 2.7% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Announcement • Oct 30
Vivo Bio Tech Limited to Report Q2, 2023 Results on Nov 14, 2022 Vivo Bio Tech Limited announced that they will report Q2, 2023 results on Nov 14, 2022 Valuation Update With 7 Day Price Move • Sep 02
Investor sentiment improved over the past week After last week's 15% share price gain to ₹36.85, the stock trades at a trailing P/E ratio of 42.9x. Average trailing P/E is 38x in the Life Sciences industry in India. Total returns to shareholders of 20% over the past three years. Announcement • Aug 31
Vivo Bio Tech Limited, Annual General Meeting, Sep 28, 2022 Vivo Bio Tech Limited, Annual General Meeting, Sep 28, 2022, at 15:00 Indian Standard Time. Reported Earnings • Aug 12
First quarter 2023 earnings released: EPS: ₹0.22 (vs ₹0.87 in 1Q 2022) First quarter 2023 results: EPS: ₹0.22 (down from ₹0.87 in 1Q 2022). Revenue: ₹112.6m (down 13% from 1Q 2022). Net income: ₹3.16m (down 75% from 1Q 2022). Profit margin: 2.8% (down from 9.5% in 1Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 2% per year and the company’s share price has also increased by 2% per year. Announcement • Jul 30
Vivo Bio Tech Limited to Report Q1, 2023 Results on Aug 10, 2022 Vivo Bio Tech Limited announced that they will report Q1, 2023 results at 3:30 PM, Indian Standard Time on Aug 10, 2022 Valuation Update With 7 Day Price Move • Jun 17
Investor sentiment deteriorated over the past week After last week's 19% share price decline to ₹30.55, the stock trades at a trailing P/E ratio of 20.6x. Average trailing P/E is 32x in the Life Sciences industry in India. Total loss to shareholders of 14% over the past three years. Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment improved over the past week After last week's 22% share price gain to ₹48.20, the stock trades at a trailing P/E ratio of 21.6x. Average trailing P/E is 36x in the Life Sciences industry in India. Total loss to shareholders of 9.1% over the past three years. Valuation Update With 7 Day Price Move • Feb 09
Investor sentiment deteriorated over the past week After last week's 30% share price decline to ₹48.35, the stock trades at a trailing P/E ratio of 21.6x. Average trailing P/E is 36x in the Life Sciences industry in India. Total loss to shareholders of 19% over the past three years. Reported Earnings • Feb 04
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹0.97 (down from ₹1.73 in 3Q 2021). Revenue: ₹129.2m (up 8.8% from 3Q 2021). Net income: ₹13.7m (down 38% from 3Q 2021). Profit margin: 11% (down from 19% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Jan 04
Investor sentiment improved over the past week After last week's 15% share price gain to ₹73.55, the stock trades at a trailing P/E ratio of 25.4x. Average trailing P/E is 33x in the Life Sciences industry in India. Total returns to shareholders of 4.5% over the past three years. Reported Earnings • Nov 07
Second quarter 2022 earnings released: EPS ₹0.20 (vs ₹1.63 in 2Q 2021) The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2022 results: Revenue: ₹102.0m (down 31% from 2Q 2021). Net income: ₹2.77m (down 87% from 2Q 2021). Profit margin: 2.7% (down from 14% in 2Q 2021). The decrease in margin was driven by lower revenue. Valuation Update With 7 Day Price Move • Sep 20
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₹75.65, the stock trades at a trailing P/E ratio of 18.1x. Average trailing P/E is 24x in the Life Sciences industry in India. Total returns to shareholders of 32% over the past three years. Valuation Update With 7 Day Price Move • Aug 30
Investor sentiment improved over the past week After last week's 38% share price gain to ₹98.95, the stock trades at a trailing P/E ratio of 22.9x. Average trailing P/E is 40x in the Life Sciences industry in India. Total returns to shareholders of 52% over the past three years. Reported Earnings • Aug 19
First quarter 2022 earnings released: EPS ₹0.87 (vs ₹0.76 in 1Q 2021) The company reported a solid first quarter result with improved earnings and revenues, although profit margins were weaker. First quarter 2022 results: Revenue: ₹132.2m (up 44% from 1Q 2021). Net income: ₹12.4m (up 27% from 1Q 2021). Profit margin: 9.4% (down from 11% in 1Q 2021). The decrease in margin was driven by higher expenses. Reported Earnings • Jul 02
Full year 2021 earnings released: EPS ₹4.23 (vs ₹3.45 in FY 2020) The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2021 results: Revenue: ₹518.5m (down 6.3% from FY 2020). Net income: ₹56.8m (up 28% from FY 2020). Profit margin: 11% (up from 8.0% in FY 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jun 11
Investor sentiment improved over the past week After last week's 16% share price gain to ₹87.45, the stock trades at a trailing P/E ratio of 22.6x. Average trailing P/E is 43x in the Life Sciences industry in India. Total returns to shareholders of 62% over the past three years. Valuation Update With 7 Day Price Move • Apr 24
Investor sentiment improved over the past week After last week's 20% share price gain to ₹61.65, the stock trades at a trailing P/E ratio of 15.9x. Average trailing P/E is 52x in the Life Sciences industry in India. Total returns to shareholders of 1.8% over the past three years. Valuation Update With 7 Day Price Move • Mar 01
Investor sentiment improved over the past week After last week's 15% share price gain to ₹59.95, the stock is trading at a trailing P/E ratio of 15.5x, up from the previous P/E ratio of 13.5x. This compares to an average P/E of 45x in the Life Sciences industry in India. Total return to shareholders over the past three years is a loss of 3.7%. Reported Earnings • Feb 12
Third quarter 2021 earnings released: EPS ₹1.73 (vs ₹1.02 in 3Q 2020) The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2021 results: Revenue: ₹118.7m (down 16% from 3Q 2020). Net income: ₹22.3m (up 70% from 3Q 2020). Profit margin: 19% (up from 9.3% in 3Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Announcement • Feb 02
Vivo Bio Tech Limited to Report Q3, 2021 Results on Feb 10, 2021 Vivo Bio Tech Limited announced that they will report Q3, 2021 results on Feb 10, 2021 Valuation Update With 7 Day Price Move • Jan 04
Investor sentiment improved over the past week After last week's 25% share price gain to ₹65.30, the stock is trading at a trailing P/E ratio of 21.2x, up from the previous P/E ratio of 17x. This compares to an average P/E of 37x in the Life Sciences industry in India. Total returns to shareholders over the past three years are 31%. Is New 90 Day High Low • Dec 31
New 90-day high: ₹54.60 The company is up 41% from its price of ₹38.60 on 01 October 2020. The Indian market is up 20% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 20% over the same period. Valuation Update With 7 Day Price Move • Dec 24
Investor sentiment improved over the past week After last week's 16% share price gain to ₹52.35, the stock is trading at a trailing P/E ratio of 17x, up from the previous P/E ratio of 14.7x. This compares to an average P/E of 37x in the Life Sciences industry in India. Total returns to shareholders over the past three years are 7.9%. Recent Insider Transactions • Dec 02
COO & Head of Business Development recently sold ₹288k worth of stock On the 27th of November, Kalyan Korisapati sold around 6k shares on-market at roughly ₹47.84 per share. This was the largest sale by an insider in the last 3 months. This was Kalyan's only on-market trade for the last 12 months. Is New 90 Day High Low • Nov 24
New 90-day high: ₹53.40 The company is up 13% from its price of ₹47.25 on 26 August 2020. The Indian market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 9.0% over the same period. Announcement • Nov 03
Vivo Bio Tech Limited to Report Q2, 2021 Results on Nov 11, 2020 Vivo Bio Tech Limited announced that they will report Q2, 2021 results on Nov 11, 2020 Valuation Update With 7 Day Price Move • Oct 28
Market pulls back on stock over the past week After last week's 21% share price decline to ₹40.70, the stock is trading at a trailing P/E ratio of 12.5x, down from the previous P/E ratio of 15.7x. This compares to an average P/E of 40x in the Life Sciences industry in India. Total return to shareholders over the past three years is a loss of 26%. Valuation Update With 7 Day Price Move • Oct 21
Market bids up stock over the past week After last week's 15% share price gain to ₹49.55, the stock is trading at a trailing P/E ratio of 15.2x, up from the previous P/E ratio of 13.1x. This compares to an average P/E of 41x in the Life Sciences industry in India. Total return to shareholders over the past three years is a loss of 17%. Valuation Update With 7 Day Price Move • Oct 19
Market bids up stock over the past week After last week's 16% share price gain to ₹44.85, the stock is trading at a trailing P/E ratio of 13.7x, up from the previous P/E ratio of 11.8x. This compares to an average P/E of 42x in the Life Sciences industry in India. Total return to shareholders over the past three years is a loss of 29%. Valuation Update With 7 Day Price Move • Oct 14
Market bids up stock over the past week After last week's 16% share price gain to ₹42.95, the stock is trading at a trailing P/E ratio of 13.1x, up from the previous P/E ratio of 11.3x. This compares to an average P/E of 54x in the Life Sciences industry in India. Total return to shareholders over the past three years is a loss of 31%. Announcement • Aug 31
Vivo Bio Tech Limited announced that it expects to receive INR 81 million in funding Vivo Bio Tech Limited (BSE:511509) announced a private placement of up to 18,00,000 equity share warrants at a price of INR 45 per warrant for gross proceeds of INR 81,000,0000 on August 28, 2020. The transaction has been approved by the company's board of directors. The warrants will be issued on a preferential basis to promoter group. The warrants will be issued at a premium of INR 35 per warrant. Announcement • Aug 20
Vivo Bio Tech Limited to Report Q1, 2020 Results on Aug 28, 2020 Vivo Bio Tech Limited announced that they will report Q1, 2020 results on Aug 28, 2020